Corsera Health
Boston
About Corsera Health
Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing the production of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $130.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: corserahealth.com
Industries & Categories
Biotechnology, Emergency Medicine, Medical
Social Profiles
Canonical: https://fsome.com/organization/corsera-health-2956 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.